# François Guilhot

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/francois-guilhot/

## Facts

| Field | Value |
| --- | --- |
| Citations | 41,972 |
| Field | Chronic Myeloid Leukemia Treatments |
| h-index | 82 |
| i10-index | 282 |
| Last Known Institution | Inserm |
| OpenAlex ID | https://openalex.org/A5079181777 |
| ORCID iD | https://orcid.org/0000-0001-7222-487X |
| Works | 588 |

## Researcher papers

- [European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia](https://scholariq.org/papers/european-leukemianet-2020-recommendations-for-treating-chronic-myeloid-leukemia/)
- [Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial](https://scholariq.org/papers/discontinuation-of-tyrosine-kinase-inhibitor-therapy-in-chronic-myeloid/)
- [Quality of Life in Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia on Imatinib Versus Interferon Alfa Plus Low-Dose Cytarabine: Results From the IRIS Study](https://scholariq.org/papers/quality-of-life-in-patients-with-newly-diagnosed-chronic-phase-chronic-myeloid/)

## Researcher topics

- [Chronic Myeloid Leukemia Treatments](https://scholariq.org/topics/chronic-myeloid-leukemia-treatments/)
- [Chronic Lymphocytic Leukemia Research](https://scholariq.org/topics/chronic-lymphocytic-leukemia-research/)
- [Eosinophilic Disorders and Syndromes](https://scholariq.org/topics/eosinophilic-disorders-and-syndromes/)
- [Acute Lymphoblastic Leukemia research](https://scholariq.org/topics/acute-lymphoblastic-leukemia-research/)
- [Acute Myeloid Leukemia Research](https://scholariq.org/topics/acute-myeloid-leukemia-research/)

## Researcher university

- [Inserm](https://scholariq.org/institutions/inserm/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.